Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less
NCT ID: NCT05193253
Last Updated: 2022-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
119 participants
OBSERVATIONAL
2000-02-01
2021-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
NCT02535117
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
NCT03313648
Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma
NCT01768741
A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
NCT02482909
Non Transplantable Recurrence After Percutaneous Thermal Ablation of HCC
NCT05202184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solitary HCC <= 3 cm
Treatment-naive patients with HCC \<= 3 cm
Radiofrequency ablation
Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
Liver resection
Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
Liver transplantation
Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiofrequency ablation
Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
Liver resection
Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
Liver transplantation
Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Solitary HCC ≤ 3cm
* Receipt of either radiofrequency ablation, liver resection, or listing for a liver transplant
* Treatment received between Feb-2000 and Nov-2018
Exclusion Criteria
* Receipt of prior treatment (i.e., not treatment naive)
* Not eligible for all of the three treatments (ablation, liver resection, or liver transplant listing)
* Platelet count \<100,000 before treatment
* Alpha-1 fetoprotein (AFP) level \> 1000 before treatment
* Age \> 70 years
* Child-Pugh score C
* Esophageal varices grade greater than 2
* Model for End-stage Liver Disease (MELD) score before treatment exceeding 15
* Presence of ascites pretreatment
* Presence of encephalopathy pretreatment
* Spleen size greater than 12 cm
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-5285.6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.